

Baxter International Inc.
Net Sales from Continuing Operations
Period Ending September 30, 2004
(unaudited)

(\$ in millions)	Q3 2004	Q3 2003	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2004	YTD 2003	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
United States	\$408	\$395	3%	3%	\$1,196	\$1,058	13%	13%
International	441	425	4%	(3%)	1,356	1,275	6%	(3%)
Total	\$849	\$820	4%	0%	\$2,552	\$2,333	9%	4%
Medication Delivery								
United States	\$593	\$575	3%	3%	\$1,716	\$1,668	3%	3%
International	393	370	6%	1%	1,202	1,062	13%	5%
Total	\$986	\$945	4%	2%	\$2,918	\$2,730	7%	4%
Renal								
United States	\$101	\$97	4%	4%	\$303	\$294	3%	3%
International	384	354	8%	4%	1,135	1,016	12%	5%
Total	\$485	\$451	8%	4%	\$1,438	\$1,310	10%	4%
Baxter International Inc.								
United States	\$1,102	\$1,067	3%	3%	\$3,215	\$3,020	6%	6%
International	1,218	1,149	6%	0%	3,693	3,353	10%	2%
Total	\$2,320	\$2,216	5%	2%	\$6,908	\$6,373	8%	4%

Note: In August 2004, the company restated its previously issued financial statements for 2001 through 2003 and the first quarter of 2004. This information reflects the restatements. Refer to the company's Form 10-K/A for the year ended December 31, 2003 and Forms 10-Q/A for the quarters ended March 31, 2004 and September 30, 2003 for further information.